Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Sure bet that it will slowly rise back to 80p and then back to higher levels once we near the end of p3. Avion are going for the US market and the p3 will be designed to the results of the previous p3. To get through fda and passed is still tough but the odds are in favour. Aimo.
It is concerning that there does not appear to be any action forthcoming from the company. There were a lot of promises made by TM earlier this year with regards to plenty of positive new flow. Yet here we are at a record low share price and silence. Hard to believe that Its coming up to two years since the phase 3 announcement and the promises of a partnership.
The slide in the share price is purely down to the fact that we are running out of money and a dilution looks to be on the cards to keep the company going. I will continue to average down as I still think there is a product here. Problem is at what price?
At least we have clarity that there will be another phase 3 trial that will be targeted specifically to those patients that did well. If so then risk of failure next time round is greatly reduced. This could be a very good time to buy as collaboration news could come at any time.
No. They are suspended and will be delisted.
don't assume they got the money because results are good. afterall the same was being said when they raised 10m just before the p3 results were announced and we all know how that turned out.
if they know the results are good then why not wait and get funding at a much higher price?
If the results are good then we will get the RNS tomorrow. If not then the likelihood of bad results (in my opinion) is increased.
Unfortunately this is feeling like a repeat of the P3 announcement that also was held back until the last minute. I hope history isn't about to repeat itself.
There has been a lot of misleading statements made on this issue. "It is important to remember that in the United States, when phase III clinical trials show a new drug is more effective and/or safer than the current standard treatment, a new drug application (NDA) is submitted to the Food and Drug Administration (FDA) for approval" The key part there is `...a new drug is more effective OR safer than the current standard treatment" I don't think that there is any doubt that Lupus has an unmet need for a safer alternative treatment. If any of you have been following the company's announcements you would have picked up on the number of times they mention its safe profile. I certainly have. And that ladies and gentlemen is the reason this is still going to happen.
There has been a lot of misleading statements made on this issue. "It is important to remember that in the United States, when phase III clinical trials show a new drug is more effective and/or safer than the current standard treatment, a new drug application (NDA) is submitted to the Food and Drug Administration (FDA) for approval" The key part there is `...a new drug is more effective OR safer than the current standard treatment" I don't think that there is any doubt that Lupus has an unmet need for a safer alternative treatment. If any of you have been following the company's announcements you would have picked up on the number of times they mention its safe profile. I certainly have. And that ladies and gentlemen is the reason this is still going to happen.
New lupus drug: not immunosuppressive, fewer side effects LupuzorTM is the first non-immunosuppressive drug for lupus. Now there are promising data from the phase III clinical trial. A marketing approval is considered likely this year. "Market launch planned for 2018 The Phase III clinical trial began in late December 2015 with one patient in the US and later expanded to Europe. A total of 202 patients were included, divided into two groups: the first group received LupuzorTM and the second group a placebo. All patients also took other medications such as steroids, antimalarials, methotrexates, etc. LupuzorTM was developed by the team of researchers led by Sylviane Muller from the Laboratory of Immunopathology and Therapeutic Chemistry of the French Center for Scientific Research CNRS and has already been successfully tested by ImmuPharma France in Phase I and Phase II clinical trials. Due to the positive Phase III study results, the manufacturer now wants to apply for approval quickly. The launch in the US and five EU countries is scheduled for 2018." from https://www.gesundheitsstadt-berlin.de/neues-lupus-medikament-nicht-immunsuppressiv-weniger-nebenwirkungen-12275/
Nice to see they have updated their website. I was also very interested to see they have made a prominent reference to the previous licencing deal with Cephalon. If that isn't a clear message of what they are expecting in terms of value then I don't know what is.